Skip to main content
Clinical Trials/NCT01153555
NCT01153555
Completed
Not Applicable

Fractional Flow Reserve and Intravascular Ultrasound RelationShip STudy: The FIRST Study

Volcano Corporation1 site in 1 country350 target enrollmentSeptember 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Volcano Corporation
Enrollment
350
Locations
1
Primary Endpoint
Correlation between (Minimum Luminal Area) MLA and FFR
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

This is a multi-center, prospective registry of patients with intermediate coronary lesions defined as a stenosis of 40-80% by angiography. Approximately 300 patients will be enrolled into the study at sites in the United States and Europe. There will be no follow up beyond hospital discharge in this study. A sub-group of 30 patients will undergo Adenosine MRI. The investigators hypothesize that Intravascular Ultrasound Radiofrequency (IVUS RF) anatomical criteria, such as minimal luminal area, plaque burden and virtual histology plaque type, can predict physiological ischemia by Fractional Flow Reserve (FFR).

Detailed Description

Patients undergoing cardiac catheterization must meet clinical inclusion and exclusion criteria and sign an informed consent. At the time of catheterization the patients will be further analyzed for eligibility using angiographic inclusion and exclusion criteria. Patients who fulfilled the clinical and angiographic criteria will undergo further imaging evaluation using an IVUS RF catheter (Volcano Therapeutics) and FFR wire (Radi or Volcano). The decision for treatment of any lesion will be at the operator's discretion. For patients enrolled at Washington Hospital Center and do not undergo percutaneous coronary intervention, an assessment with non invasive perfusion adenosine MRI also be performed.

Registry
clinicaltrials.gov
Start Date
September 2010
End Date
June 2012
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Sign written informed consent to participate in the study.
  • Clinical indication for coronary angiography for stable or unstable angina
  • Specific Angiographic Inclusion Criteria:
  • Patients required to have an intermediate coronary lesion (stenosis 40-80% by visual estimate) in one or more native, major epicardial coronary artery with reference diameter ≥2.5mm (visual estimate)
  • The vessel(s) with the intermediate lesion must have no flow limiting lesions and must be available for imaging and must be considered safe for imaging evaluation.

Exclusion Criteria

  • Patient has had a documented acute ST-segment elevation myocardial infarction within the past 24 hours
  • Decompensated heart failure or hypotension requiring intubation, inotropes, intravenous diuretics or intraaortic balloon counterpulsation.
  • Renal dysfunction (creatinine clearance \< 60 mL/min/1.73m2)
  • Pregnancy or breast-feeding
  • Standard contra-indications to MRI for implanted ferro-magnetic devices - i.e.: pacemakers, defibrillator (AICD), and aneurysm clips
  • Body weight \> 400lbs
  • Left ventricular hypertrophy \>1.5cm by by echocardiogram
  • History of bronchospasm or asthma
  • ECG evidence of conduction defect, including 2nd or 3rd degree AVB
  • Patient has a known hypersensitivity, allergy or contraindication to gadolinium-based contrast agents.

Outcomes

Primary Outcomes

Correlation between (Minimum Luminal Area) MLA and FFR

Time Frame: Day of Procedure

The correlation between MLA and FFR; and the threshold value for MLA corresponding to an FFR \< 0.8.

Secondary Outcomes

  • Correlation between FFR and IVUS and VH parameters(Day of Procedure)
  • Identify risk score model(1 year)
  • Association of FFR and Cut-off of MLA(Day of Procedure)

Study Sites (1)

Loading locations...

Similar Trials